Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

157 results about "Superparamagnetic iron oxide" patented technology

Macrophage-Enhanced MRI (MEMRI)

Methods for assessing stage of cancer in a subject are provided, comprising administering a macrophage imaging agent to the subject, making a magnetic resonance image of regions of the subject's body at cancer risk, and using the image to assess macrophage density and displacement associated with any primary cancer or metastatic cancer in the subject, such density and displacement being indicative of neoplasia. The macrophage imaging agent may be an ultrasmall superparamagnetic iron oxide particle and in particular embodiments, the macrophage imaging agent has a blood half-life sufficient to permit microphage trapping throughout the regions at cancer risk. Additional embodiments provide methods for assessing efficacy of an anticancer treatment in a subject, methods for determining frequency of follow-up MEMRI evaluation in a subject, methods for determining metastatic potential of cancer foci in a subject, and methods for determining prognosis of cancer in a subject. Methods for directing site of biopsy in a subject by performing a whole body MEMRI evaluation of the subject to identify macrophage density at a tumor site of interest and assessing the macrophage density to identify the site of biopsy in the subject, macrophage density being an indicator of tumor growth are also provided, in addition to methods for providing individualized cancer treatment to a subject in need thereof using whole body MEMRI evaluation.
Owner:AMAG PHARMA

D-glucosamine-modified iron oxide nanoparticles and preparation method of lyophilized powder thereof

The invention relates to d-glucosamine-modified iron oxide nanoparticles used as a tracer for magnetic resonance, a preparation method of lyophilized powder thereof and use thereof. The d-glucosamine-modified iron oxide nanoparticles comprise superparamagnetic iron oxide nanoparticles, wherein the surfaces of the superparamagnetic iron oxide nanoparticles are modified by a substance having carboxyls; the carboxyls react with the aminos of the d-glucosamine to form amido bonds; and thus a structure that the surfaces of the superparamagnetic iron oxide nanoparticles are modified by the d-glucosamine is formed. The invention provides a novel tumor-targeted MRI contrast agent which has high selectivity of tumors for the tumor targeted magnetic resonance diagnostic tests and clinic tumor diagnosis. By preserving the d-glucosamine-modified superparamagnetic iron oxide nanoparticles in form of the lyophilized powder, the unstable problem of the d-glucosamine-modified superparamagnetic iron oxide nanoparticles is solved. The d-glucosamine-modified iron oxide nanoparticles are sterile, anhemolytic and free from vascular stimulation and can meet the requirements of tests of cells, animals and the like.
Owner:ZHENJIANG NO 1 PEOPLES HOSPITAL +1

Novel mesoporous silicon sphere co-loaded medicine nano-complex and preparation method thereof

The invention discloses a novel mesoporous silicon sphere co-loaded medicine nano-complex and a preparation method thereof. The novel mesoporous silicon sphere co-loaded medicine nano-complex is Ce6@MMSN / DOX / Ko143@PAsp-b-PEG-FA; the preparation method comprises the following steps: selecting TEOS (Tetraethyl Orthosilicate) as a silicon source, CTAB (Cetyltrimethyl Ammonium Bromide) as a template agent and n-hexane as a pore expanding agent and synthesizing mesoporous silicon dioxide nanoparticles with a double-pore-channel core-shell structure; carrying out amination modification on the mesoporous silicon dioxide nanoparticles; synthesizing Fe3O4 nanoparticles by adopting an LSS (Liquid-Solid-Solution) phase transfer method and ligand exchange reaction; modifying and embedding superparamagnetic iron oxide nanoparticles on the surface of aminated MSN through nucleophilic substitution, so as to construct magnetic mesoporous silicon dioxide nanoparticles; taking DCC (Dicyclollexyl Carbodiimide) as a condensation agent and covalently binding a photosensitizer Ce6 through amidation; meanwhile, loading a BCRP (Breast Cancer Resistance Protein) inhibitor Ko143; then crossly linking a copolymer FA-PEG-b-PAsp; finally, loading an anti-tumor medicine DOX.
Owner:SECOND AFFILIATED HOSPITAL SECOND MILITARY MEDICAL UNIV

An acid-responsive nanometer micelle for drug loading, a preparation method and an application thereof

The invention discloses an acid-responsive nanometer micelle for drug loading, a preparation method and an application thereof. The nano-micelles were self-assembled from hydrophilic segment polyethylene glycol (PEG) and hydrophobic segment pH-sensitive polyaspartyl diisopropylethylenediamine/di-n-butylethylenediamine (PAsp (DIP/DBA)). The nano-micelles can prolong the drug circulation time, aggregate in the tumor site, increase the local drug concentration, and respond to the micro-acid environment of the tumor tissue. As a drug carrier of stimulation response, the nano-micelles can rapidly release the loaded chemotherapeutic drug adriamycin in the tumor site, and play a significant anti-tumor effect. At the same time, the nano-micelles loaded with magnetic resonance contrast agent superparamagnetic iron oxide can be used for tumor magnetic resonance imaging and monitoring drug uptake and aggregation. This method utilizes nano-drug aggregation at tumor site and acid responsiveness ofcarrier to realize rapid drug release to improve tumor therapeutic effect, and endows nano-micellar MRI visualization function, which provides a promising innovative strategy for cancer diagnosis andtreatment, and has broad application prospects.
Owner:THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV

Preparation method and application of RGD@BBN double-targeted MR (magnetic resonance)/optical dual-mode molecular probe

The invention discloses a preparation method and application of an RGD@BBN double-targeted MR (magnetic resonance)/optical dual-mode molecular probe, wherein the RGD@BBN double-targeted MR/optical dual-mode molecular probe is prepared by the following steps: coating water-soluble superparamagnetic iron oxide ( SPIO) particles in hydrophilic core of lipidosome and coating oil-soluble QDs particles in hydrophobic lipid bilayer of the lipidosome by taking lipidosome as a carrier, and linking a double-targeted RGD@BBN ligand by virtue of a post-interpolation method. The RGD@BBN contained in the dual-mode molecular probe disclosed by the invention is interpolated and immobilized on the surface of the lipid bilayer by virtue of self-assembly, and the preparation method is mild in condition and is efficient and practical. According to the invention, a relatively independent space is coated by two different image contrast agents without changing the properties of the image contrast agents; and the prepared double-target dual-mode molecular probe, which simultaneously has RGD and BBN targeting functions, has targeting functions on RGD or (and) BBN receptor-positive tumors.
Owner:GUANGZHOU FIRST PEOPLES HOSPITAL (GUANGZHOU DIGESTIVE DISEASE CENT GUANGZHOU FIRST PEOPLES HOSPITAL GUANGZHOU MEDICAL UNIV THE SECOND AFFILIATED HOSPITAL OF SOUTH CHINA UNIV OF TECH)

Stable nanoscale superparamagnetic iron oxide solution as well as preparation method and application thereof

InactiveCN103316361AGood dispersionImprove contrast imaging capabilitiesNMR/MRI constrast preparationsStage tumorSuperparamagnetic iron oxide
The invention provides a stable nanoscale superparamagnetic iron oxide solution which is used as a contrast agent for magnetic resonance imaging (MRI). The superparamagnetic iron oxide solution is characterized in that the particle size of nanoscale superparamagnetic iron oxide particles is stabilized to between 60 and 75 nanometers when the superparamagnetic iron oxide solution is stored for 12 months at an environmental temperature of 4 to 38 DEG C, and the nanoscale superparamagnetic iron oxide particles are in high dispersibility and free from agglomerating or precipitating. After nanoscale superparamagnetic iron oxide solution containing 25mcg of iron, provided by the invention, is subjected to intravenous injection in the MRI of an early-stage in-situ hepatic cancer tumor live model of a rat, the imaging performance of the tumor in the MRI is obviously improved, the position, boundary and size of the tumor can be clearly displayed, and the tumor image effect remains significant after 24 hours; the phenomenon that the boundary and size of the tumor are unclear occurs in the MRI of the early-stage in-situ hepatic cancer tumor live model without contrast agent. Therefore, the nanoscale superparamagnetic iron oxide solution provided by the invention has a stable nanometer solution characteristic, is obvious in tumor impacting effect under low-dosage injection, and unique in innovation and application prospect.
Owner:桑迪(武汉)生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products